Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

n. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II. Angiotensin II is a small peptide in the body and part of the so-called renin-angiotensin system (RAS), an important regulator of blood pressure. Angiotensin II causes blood vessels to narrow,
resulting in increased blood pressure. In a phase IIa clinical trial, vaccination with CYT006-AngQb has been shown to reduce blood pressure by induction of antibodies that bind angiotensin II. Thereby, binding of angiotensin II to its receptors and subsequent narrowing of blood vessels should be decreased. The RAS has already been successfully targeted by three major classes of antihypertensive drugs on the market: inhibitors of the angiotensin-converting-enzyme (ACE), antagonists of the angiotensin II type I receptor (ARBs) and renin inhibitors. Like other antihypertensive drugs these also come with the need for daily dosing and fail to provide a solution for improving patient compliance. Treatment with CYT006-AngQb should allow for convenient dosing schedules and smooth control of blood pressure due to a sustained antibody response induced by vaccination.



About Cytos Biotechnology AG
Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the ImmunodrugsTM. ImmunodrugsTM are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. ImmunodrugsTM are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its ImmunodrugTM platform, Cytos Biotechnology has built a pipeline of different ImmunodrugTM candidates in various disease areas, of which 6 are currently in clinical development. The Imm
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, Inc. ... its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem ... of its 6.75% Senior Notes due 2017, CUSIP Nos. ... 2014 and has mailed an irrevocable notice of redemption ... a copy of the irrevocable notice of redemption with ...
(Date:9/15/2014)... TAMPA, Fla. , Sept. 15, 2014 ... Dr. Steven Stanos with an expanded role ... program. Dr. Stanos, a nationally recognized physiatrist ... on topics related to rehabilitation and workers, compensation, is ... medicine by the American Board of Pain Medicine and ...
(Date:9/15/2014)... PDL BioPharma, Inc. (PDL) (NASDAQ: ... September 12, 2014, regular quarterly dividend payment of $0.15 per ... of September 5, 2014, the record date. ... portfolio of patents and royalty assets, consisting primarily of ... agreements with various biotechnology and pharmaceutical companies. PDL pioneered ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... NJ, Aug. 18 /PRNewswire-Asia/ -- ... ... var shortURL = ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... On August 9, 2010 Massachusetts passed Chapter 283 ... Prescription Monitoring Program and furthering Substance Abuse Education and ... in Massachusetts that dispense schedule II, III, IV, or ... sale at each location. More info at http://www.mass.gov/legis/laws/seslaw10/sl100283.htm ...
Cached Medicine Technology:Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 2Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 3Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 4Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 5Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 6New Law Requires Pharmacies in Massachusetts to Carry Rx Lock Boxes 2
(Date:9/16/2014)... Hills, CA (PRWEB) September 16, 2014 ... announce the launch of ACLsurgeryLA.com , a specialty ... ACL injuries. As an avid sports lover and ... options for treatment and recovery from injuries to maintain ... opportunity to offer patients a resource dedicated specifically to ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 *To find out ... visit Achieve Clinical Research on the web ( http://www.achieveclinical.com/trial/pneumonia-vaccine/ ) ... who qualify:, There is no cost ... , Compensation may be provided for time and ... and influenza are the eighth leading cause of death in ...
(Date:9/16/2014)... DeLand, Florida (PRWEB) September 16, 2014 ... clinical trials being conducted in DeLand, FL can visit ... or contact them directly at (386) 785-2404. , Why ... of the most widespread viral diseases infecting mankind. While ... past, these colds still account for more annual visits ...
(Date:9/16/2014)... 2014 justthoughtyoushouldknow.org , popular ... launches their new site today. The new site ... at making information easier to find, ingest, and ... into one-page, easy-to-read pages the information that we ... Virginia Downie, retired college professor and founder of ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3Health News:JustThoughtYouShouldKnow.org Debuts New Website 2
... Dec. 6 Arete Therapeutics Inc., a,privately-held biopharmaceutical ... of cardiovascular, inflammatory and,metabolic diseases, today announced the ... directors., "We are very pleased to welcome ... and operational insights will be of great benefit ...
... Name Also Unveiled in Ongoing Preparation for ... Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical company ... cancer, announced that new data,including four-year follow-up ... of Specifid(TM) (formerly FavId(R)), will be reported ...
... Oncology, the nation,s leading,oncology services company, today named ... and chief operating officer. The appointment,becomes effective on ... experience, combined with his work in,large diversified healthcare ... Broussard, president of US Oncology.,"His proven success in ...
... first increase in U.S.,teen pregnancy rates, WASHINGTON, Dec. ... pregnancy rates in the United States over the,last fourteen ... should not come as a surprise since the dual ... -- the decline in sexual,initiation and more effective use ...
... http://feeds.feedburner.com/OrthoWomensHealthAndUrology , RARITAN, NJ, December 5 Jane ... about the Pill as part of The Modern,Girl,s Guide ... Girl,s Guide to the Pill, When: The Podcast ... Where: http://feeds.feedburner.com/OrthoWomensHealthAndUrology , How: Go to ...
... With the popularity of,fillers becoming mainstream, it,s no ... prevent facial wrinkles. Dr. Arnold Klein, world,renowned cosmetic ... "Fillers such as Artefill, Radiesse and Sculptra contain ... tissue, all of,these products can cause foreign body ...
Cached Medicine News:Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 3Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 4Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 5Health News:US Oncology Appoints Glen Laschober EVP & Chief Operating Officer 2Health News:Facial Deformity Danger? 2
...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Medicine Products: